A trial comparing standard dose chemotherapy with high dose chemotherapy for advanced ovarian or fallopian tube cancer (HIDOC EIS)

Cancer type:

Ovarian cancer

Status:

Results

Phase:

Phase 3

This trial compared standard dose chemotherapy with high dose chemotherapy and stem cell transplants for women with advanced ovarian or fallopian tube cancer.

Doctors usually treat ovarian and fallopian tube cancers with surgery and chemotherapy. But if the cancer has already spread when it is first diagnosed, it can be more difficult to treat. Doctors wanted to find out if higher doses of chemotherapy followed by stem cell transplants were useful for this group of patients. All women taking part had surgery to remove as much of their cancer as possible before chemotherapy.

The aims of the trial were to find out

  • Which treatment works better for women who have not had chemotherapy for their advanced cancer before
  • More about the side effects

Summary of results

The research team found that having more than one cycle of high dose chemotherapy and stem cell transplants were no better than the current standard chemotherapy for advanced ovarian or fallopian tube cancer.

The trial recruited 149 women aged between 20 and 65 after they had had surgery.

  • Half had standard chemotherapy
  • Half had high dose chemotherapy and stem cell transplants with their own cells

The researchers looked at the number of women whose cancer came back, and the number of women who were alive 3 years after treatment. They found that there was no difference between the two groups.

The main side effects both treatments were

The women who had high dose chemotherapy and stem cell transplants had more severe side effects than the women who had standard treatment. Fewer were able to finish their treatment because of this.

We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (peer reviewed) and published in a medical journal. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor Jonathan Ledermann

Supported by

Amgen
European Blood and Bone Marrow Transplant Group
NIHR Clinical Research Network: Cancer

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 79

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Around 1 in 5 people take part in clinical trials

3 phases of trials

Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page